Are adolescents more vulnerable to the harmful effects of cannabis than adults? A placebo-controlled study in human males

Translational Psychiatry

Volumn 6, Issue 11, 2016, Pages

  Mokrysz, C ^a   Freeman, T P ^a   Korkki, S ^b   Griffiths, K ^c   Curran, H V ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c MRC COGNITION AND BRAIN SCIENCES UNIT   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CANNABIS; PLACEBO; PSYCHEDELIC AGENT;

ACCURACY; ADOLESCENT; ADULT; AGE; ALERTNESS; ANHEDONIA; ANXIETY; ARTICLE; CANNABIS ADDICTION; CANNABIS USE; CANNABIS-INDUCED PSYCHOSIS; CHILD PSYCHIATRY; CHILDHOOD PSYCHOSIS; CLINICAL ARTICLE; COGNITION; COGNITIVE DEFECT; COMPARATIVE STUDY; CONTROLLED STUDY; CORRELATION COEFFICIENT; DIASTOLIC BLOOD PRESSURE; EPISODIC MEMORY; HEART RATE; HUMAN; INHALANT ABUSE; INHIBITION (PSYCHOLOGY); MALE; N-BACK TEST; PSYCHOLOGICAL RESILIENCE; REACTION TIME; RECALL; RESPONSE INHIBITION; SATIETY; SPATIAL MEMORY; STOP SIGNAL REACTION TIME; SUBSTANCE ABUSE; SYSTOLIC BLOOD PRESSURE; VULNERABLE POPULATION; WORKING MEMORY; XEROSTOMIA; AROUSAL; BLOOD PRESSURE; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFECTS; INHALATIONAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL; SATIETY RESPONSE; SHORT TERM MEMORY; SPATIAL LEARNING;

ADMINISTRATION, INHALATION; ADOLESCENT; ADULT; AGE FACTORS; AROUSAL; BLOOD PRESSURE; CANNABIS; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; HEART RATE; HUMANS; INHIBITION (PSYCHOLOGY); MALE; MEMORY, EPISODIC; MEMORY, SHORT-TERM; SATIETY RESPONSE; SPATIAL LEARNING;

EID: 85032472429     PISSN: None     EISSN: 21583188     Source Type: Journal    
DOI: 10.1038/tp.2016.225     Document Type: Article

References (91)

1. Hibell B, Guttormsson U, Ahlstrom S, Balakireva O, Bjarnason T, Kokkevi A et al. The 2011 ESPAD report. Substance use among students in 36 European countries. The Swedish Council for information on Alcohol and Other Drugs, Stockholm, Sweden, 2012. Available at http://www.espad.org (accessed September 2012).
2. Grucza RA, Agrawal A, Krauss MJ, Bongu J, Plunk AD, Cavazos-Rehg PA et al. Declining prevalence of marijuana use disorders among adolescents in the United States, 2002 to 2013. J Am Acad Child Adolesc Psychiatry 2016; 55: 487–494.
3. Degenhardt L, Chiu W-T, Sampson N, Kessler RC, Anthony JC, Angermeyer M et al. Toward a global view of alcohol, tobacco, cannabis, and cocaine use: findings from the WHO World Mental Health Surveys. PLoS Med 2008; 5: e141.
4. Degenhardt L, Stockings E, Patton G, Hall WD, Lynskey M. The increasing global health priority of substance use in young people. Lancet Psychiatry 2016; 3: 251–264.
5. Morgan CJ, Page E, Schaefer C, Chatten K, Manocha A, Gulati S et al. Cerebrospinal fluid anandamide levels, cannabis use and psychotic-like symptoms. Br J Psychiatry 2013; 202: 381–382.
6. Hirvonen J, Goodwin R, Li C-T, Terry G, Zoghbi S, Morse C et al. Reversible and regionally selective downregulation of brain cannabinoid CB1 receptors in chronic daily cannabis smokers. Mol Psychiatry 2012; 17: 642–649.
7. D’Souza DC, Cortes-Briones JA, Ranganathan M, Thurnauer H, Creatura G, Surti T et al. Rapid changes in cannabinoid 1 receptor availability in cannabis-dependent male subjects after abstinence from cannabis. Biol Psychiatry Cogn Neurosci Neuroimaging 2016; 1: 60–67.
8. Ellgren M, Artmann A, Tkalych O, Gupta A, Hansen HS, Hansen S et al. Dynamic changes of the endogenous cannabinoid and opioid mesocorticolimbic systems during adolescence: THC effects. Eur Neuropsychopharmacol 2008; 18: 826–834.
9. Rubino T, Parolaro D. The impact of exposure to cannabinoids in adolescence: insights from animal models. Biol Psychiatry 2016; 79: 578–585.
10. Verdurand M, Nguyen V, Stark D, Zahra D, Gregoire M-C, Greguric I et al. Comparison of cannabinoid CB1 receptor binding in adolescent and adult rats: a positron emission tomography study using [18 F] MK-9470. Int J Mol Imaging 2011; 2011: 548123.
11. Moore NL, Greenleaf AL, Acheson SK, Wilson WA, Swartzwelder HS, Kuhn CM. Role of cannabinoid receptor type 1 desensitization in greater tetrahydrocannabinol impairment of memory in adolescent rats. J Pharmacol Exp Ther 2010; 335: 294–301.
12. Bossong MG, Niesink RJ. Adolescent brain maturation, the endogenous cannabinoid system and the neurobiology of cannabis-induced schizophrenia. Prog Neurobiol 2010; 92: 370–385.
13. Lubman DI, Cheetham A, Yücel M. Cannabis and adolescent brain development. Pharmacol Ther 2015; 148: 1–16.
14. Rubino T, Prini P, Piscitelli F, Zamberletti E, Trusel M, Melis M et al. Adolescent exposure to THC in female rats disrupts developmental changes in the prefrontal cortex. Neurobiol Dis 2015; 73: 60–69.
15. Cass DK, Flores-Barrera E, Thomases DR, Vital WF, Caballero A, Tseng KY. CB1 cannabinoid receptor stimulation during adolescence impairs the maturation of GABA function in the adult rat prefrontal cortex. Mol Psychiatry 2014; 19: 536.
16. Curran HV, Freeman TP, Mokrysz C, Lewis DA, Morgan CJ, Parsons LH. Keep off the grass? Cannabis, cognition and addiction. Nat Rev Neurosci 2016; 17: 293–306.
17. Hanson KL, Winward JL, Schweinsburg AD, Medina KL, Brown SA, Tapert SF. Longitudinal study of cognition among adolescent marijuana users over three weeks of abstinence. Addict Behav 2010; 35: 970–976.
18. Harvey MA, Harvey MA, Sellman JD, Harvey MA, Sellman JD, Porter RJ et al. The relationship between non-acute adolescent cannabis use and cognition. Drug Alcohol Rev 2007; 26: 309–319.
19. Tapert SF, Schweinsburg AD, Drummond SP, Paulus MP, Brown SA, Yang TT et al. Functional MRI of inhibitory processing in abstinent adolescent marijuana users. Psychopharmacology 2007; 194: 173–183.
20. Schweinsburg AD, Nagel BJ, Schweinsburg BC, Park A, Theilmann RJ, Tapert SF. Abstinent adolescent marijuana users show altered fMRI response during spatial working memory. Psychiatry Res 2008; 163: 40–51.
21. Batalla A, Bhattacharyya S, Yücel M, Fusar-Poli P, Crippa JA, Nogué S et al. Structural and functional imaging studies in chronic cannabis users: a systematic review of adolescent and adult findings. PloS One 2013; 8: e55821.
22. Gruber SA, Dahlgren MK, Sagar KA, Gönenç A, Lukas SE. Worth the wait: effects of age of onset of marijuana use on white matter and impulsivity. Psychopharmacology 2014; 231: 1455–1465.
23. Epstein KA, Kumra S. White matter fractional anisotropy over two time points in early onset schizophrenia and adolescent cannabis use disorder: a naturalistic diffusion tensor imaging study. Psychiatry Res 2015; 232: 34–41.
24. von Sydow K, Lieb R, Pfister H, Höfler M, Wittchen H-U. What predicts incident use of cannabis and progression to abuse and dependence?: A 4-year prospective examination of risk factors in a community sample of adolescents and young adults. Drug Alcohol Depend 2002; 68: 49–64.
25. Chen CY, Anthony JC. Possible age‐associated bias in reporting of clinical features of drug dependence: epidemiological evidence on adolescent‐onset marijuana use. Addiction 2003; 98: 71–82.
26. Chen C-Y, O’Brien MS, Anthony JC. Who becomes cannabis dependent soon after onset of use? Epidemiological evidence from the United States: 2000–2001. Drug Alcohol Depend 2005; 79: 11–22.
27. Hines LA, Morley KI, Strang J, Agrawal A, Nelson EC, Statham D et al. The association between speed of transition from initiation to subsequent use of cannabis and later problematic cannabis use, abuse and dependence. Addiction 2015; 110: 1311–1320.
28. Meier MH, Caspi A, Ambler A, Harrington H, Houts R, Keefe RS et al. Persistent cannabis users show neuropsychological decline from childhood to midlife. Proc Natl Acad Sci USA 2012; 109: E2657–E2664.
29. Gruber SA, Sagar KA, Dahlgren MK, Racine M, Lukas SE. Age of onset of marijuana use and executive function. Psychol Addict Behav 2012; 26: 496.
30. Arseneault L, Cannon M, Poulton R, Murray R, Caspi A, Moffitt TE. Cannabis use in adolescence and risk for adult psychosis: longitudinal prospective study. BMJ 2002; 325: 1212–1213.
31. Moore TH, Zammit S, Lingford-Hughes A, Barnes TR, Jones PB, Burke M et al. Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Lancet 2007; 370: 319–328.
32. Di Forti M, Sallis H, Allegri F, Trotta A, Ferraro L, Stilo SA et al. Daily use, especially of high-potency cannabis, drives the earlier onset of psychosis in cannabis users. Schizophr Bull 2014; 40: 1509–1517.
33. Verrico CD, Gu H, Peterson ML, Sampson AR, Lewis DA. Repeated Δ9-tetrahydrocannabinol exposure in adolescent monkeys: persistent effects selective for spatial working memory. Am J Psychiatry 2014; 171: 416–425.
34. Verrico CD, Liu S, Bitler EJ, Gu H, Sampson AR, Bradberry CW et al. Delay-and dose-dependent effects of Δ9-tetrahydrocannabinol administration on spatial and object working memory tasks in adolescent rhesus monkeys. Neuropsychopharmacology 2012; 37: 1357–1366.
35. Quinn HR, Matsumoto I, Callaghan PD, Long LE, Arnold JC, Gunasekaran N et al. Adolescent rats find repeated Δ9-THC less aversive than adult rats but display greater residual cognitive deficits and changes in hippocampal protein expression following exposure. Neuropsychopharmacology 2008; 33: 1113–1126.
36. Schneider M, Koch M. Chronic pubertal, but not adult chronic cannabinoid treatment impairs sensorimotor gating, recognition memory, and the performance in a progressive ratio task in adult rats. Neuropsychopharmacology 2003; 28: 1760–1769.
37. O’Shea M, Singh ME, McGregor IS, Mallet PE. Chronic cannabinoid exposure produces lasting memory impairment and increased anxiety in adolescent but not adult rats. J Psychopharmacol 2004; 18: 502–508.
38. Fox KM, Sterling RC, Van Bockstaele EJ. Cannabinoids and novelty investigation: influence of age and duration of exposure. Behav Brain Res 2009; 196: 248–253.
39. Cha YM, White AM, Kuhn CM, Wilson WA, Swartzwelder H. Differential effects of delta 9-THC on learning in adolescent and adult rats. Pharmacol Biochem Behav 2006; 83: 448–455.
40. Cha YM, Jones KH, Kuhn CM, Wilson WA, Swartzwelder HS. Sex differences in the effects of Δ9-tetrahydrocannabinol on spatial learning in adolescent and adult rats. Behav Pharmacol 2007; 18: 563–569.
41. Schneider M, Schömig E, Leweke FM. PRECLINICAL STUDY: acute and chronic cannabinoid treatment differentially affects recognition memory and social behavior in pubertal and adult rats. Addict Biol 2008; 13: 345–357.
42. Acheson SK, Moore NL, Kuhn CM, Wilson WA, Swartzwelder HS. The synthetic cannabinoid WIN 55212-2 differentially modulates thigmotaxis but not spatial learning in adolescent and adult animals. Neurosci Lett 2011; 487: 411–414.
43. Carvalho A, Reyes B, Ramalhosa F, Sousa N, Van Bockstaele E. Repeated administration of a synthetic cannabinoid receptor agonist differentially affects cortical and accumbal neuronal morphology in adolescent and adult rats. Brain Struct Funct 2016; 221: 407–419.
44. Schramm-Sapyta NL, Cha YM, Chaudhry S, Wilson WA, Swartzwelder HS, Kuhn CM. Differential anxiogenic, aversive, and locomotor effects of THC in adolescent and adult rats. Psychopharmacology 2007; 191: 867–877.
45. Spear LP. Alcohol consumption in adolescence: a translational perspective. Curr Addict Rep 2016; 3: 50–61.
46. Curran VH, Brignell C, Fletcher S, Middleton P, Henry J. Cognitive and subjective dose-response effects of acute oral Δ9-tetrahydrocannabinol (THC) in infrequent cannabis users. Psychopharmacology 2002; 164: 61–70.
47. Ranganathan M, D’souza DC. The acute effects of cannabinoids on memory in humans: a review. Psychopharmacology 2006; 188: 425–444.
48. Crane NA, Schuster RM, Fusar-Poli P, Gonzalez R. Effects of cannabis on neuro-cognitive functioning: recent advances, neurodevelopmental influences, and sex differences. Neuropsychol Rev 2013; 23: 117–137.
49. Gonzalez R. Acute and non-acute effects of cannabis on brain functioning and neuropsychological performance. Neuropsychol Rev 2007; 17: 347–361.
50. Sherif M, Radhakrishnan R, D’Souza DC, Ranganathan M. Human laboratory studies on cannabinoids and psychosis. Biol Psychiatry 2016; 79: 526–538.
51. D'Souza DC, Perry E, MacDougall L, Ammerman Y, Cooper T, Wu Y-t et al. The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: implications for psychosis. Neuropsychopharmacology 2004; 29: 1558–1572.
52. Martin G, Copeland J, Gates P, Gilmour S. The Severity of Dependence Scale (SDS) in an adolescent population of cannabis users: reliability, validity and diagnostic cut-off. Drug Alcohol Depend 2006; 83: 90–93.
53. Bossong MG, van Berckel BN, Boellaard R, Zuurman L, Schuit RC, Windhorst AD et al. Δ9-tetrahydrocannabinol induces dopamine release in the human striatum. Neuropsychopharmacology 2009; 34: 759–766.
54. Hindocha C, Freeman TP, Schafer G, Gardener C, Das RK, Morgan CJ et al. Acute effects of delta-9-tetrahydrocannabinol, cannabidiol and their combination on facial emotion recognition: a randomised, double-blind, placebo-controlled study in cannabis users. Eur Neuropsychopharmacol 2014; 25: 325–334.
55. Lawn W, Freeman T, Pope R, Joye A, Harvey L, Hindocha C et al. Acute and chronic effects of cannabinoids on effort-related decision-making and reward learning: an evaluation of the cannabis ‘amotivational’ hypotheses. Psychopharmacology 2016; 233: 3537–3552.
56. van der Pol P, Liebregts N, Brunt T, Amsterdam J, Graaf R, Korf DJ et al. Cross-sectional and prospective relation of cannabis potency, dosing and smoking behaviour with cannabis dependence: an ecological study. Addiction 2014; 109: 1101–1109.
57. Lanz C, Mattsson J, Soydaner U, Brenneisen R. Medicinal Cannabis: in vitro validation of vaporizers for the smoke-free inhalation of cannabis. PloS One 2016; 11: e0147286.
58. Hazekamp A, Ruhaak R, Zuurman L, van Gerven J, Verpoorte R. Evaluation of a vaporizing device (Volcano®) for the pulmonary administration of tetrahydrocannabinol. J Pharm Sci 2006; 95: 1308–1317.
59. Abrams DI, Vizoso HP, Shade SB, Jay C, Kelly ME, Benowitz NL. Vaporization as a smokeless cannabis delivery system: a pilot study. Clin Pharmacol Ther 2007; 82: 572–578.
60. Holdnack H. Wechsler Test of Adult Reading: WTAR. The Psychological Corporation: San Antonio, TX, 2001.
61. Beck AT, Steer RA, Brown GK. Beck Depression Inventory-II. Psychological Corporation: San Antonio, TX, 1996; b9.
62. Beck AT, Epstein N, Brown G, Steer RA. An inventory for measuring clinical anxiety: psychometric properties. J Consult Clin Psychol 1988; 56: 893.
63. Lynam D. Development of a short form of the UPPS-P Impulsive Behavior Scale. Unpublished Technical Report, 2013.
64. Cyders MA, Littlefield AK, Coffey S, Karyadi KA. Examination of a short English version of the UPPS-P Impulsive Behavior Scale. Addict Behav 2014; 39: 1372–1376.
65. Raine A. The SPQ: a scale for the assessment of schizotypal personality based on DSM-III-R criteria. Schizophr Bull 1991; 17: 555.
66. Huestis MA, Henningfield JE, Cone EJ. Blood cannabinoids. I. Absorption of THC and formation of 11-OH-THC and THCCOOH during and after smoking marijuana. J Anal Toxicol 1992; 16: 276–282.
67. Legleye S, Karila L, Beck F, Reynaud M. Validation of the CAST, a general population Cannabis Abuse Screening Test. J Subst Use 2007; 12: 233–242.
68. Heatherton TF, Kozlowski LT, Frecker RC, Fagerstrom KO. The Fagerström test for nicotine dependence: a revision of the Fagerstrom Tolerance Questionnaire. Br J Addict 1991; 86: 1119–1127.
69. Babor TF, DeLaFuentes JR, Saunders J, Grant M. AUDIT: The Alcohol Use Disorders Identification Test: guidelines for use in primaryhealth care. World Health Organisation: PSA/92.4, pp 1–30, 1992.
70. Mason OJ, Morgan CJ, Stefanovic A, Curran HV. The psychotomimetic states inventory (PSI): measuring psychotic-type experiences from ketamine and cannabis. Schizophr Res 2008; 103: 138–142.
71. Morgan CJ, Schafer G, Freeman TP, Curran HV. Impact of cannabidiol on the acute memory and psychotomimetic effects of smoked cannabis: naturalistic study. Br J Psychiatry 2010; 197: 285–290.
72. Wilson B, Cockburn J, Baddeley A, Hiorns R. The development and validation of a test battery for detecting and monitoring everyday memory problems. J Clin Exp Neuropsychol 1989; 11: 855–870.
73. Braver TS, Cohen JD, Nystrom LE, Jonides J, Smith EE, Noll DC. A parametric study of prefrontal cortex involvement in human working memory. Neuroimage 1997; 5: 49–62.
74. Freeman TP, Morgan CJ, Vaughn‐Jones J, Hussain N, Karimi K, Curran HV. Cognitive and subjective effects of mephedrone and factors influencing use of a ‘new legal high’. Addiction 2012; 107: 792–800.
75. Verbruggen F, Logan GD, Stevens MA. STOP-IT: Windows executable software for the stop-signal paradigm. Behav Res Methods 2008; 40: 479–483.
76. Congdon E, Mumford JA, Cohen JR, Galvan A, Canli T, Poldrack RA. Measurement and reliability of response inhibition. Front Psychol 2012; 3: 1–10.
77. Realini N, Rubino T, Parolaro D. Neurobiological alterations at adult age triggered by adolescent exposure to cannabinoids. Pharmacol Res 2009; 60: 132–138.
78. Broyd SJ, van Hell HH, Beale C, Yücel M, Solowij N. Acute and chronic effects of cannabinoids on human cognition–a systematic review. Biol Psychiatry 2015; 79: 557–567.
79. Freeman TP, Morgan CJ, Hindocha C, Schafer G, Das RK, Curran HV. Just say ‘know’: how do cannabinoid concentrations influence users’ estimates of cannabis potency and the amount they roll in joints? Addiction 2014; 109: 1686–1694.
80. Manini TM. Energy expenditure and aging. Ageing Res Rev 2010; 9: 1–11.
81. Black AE, Coward WA, Cole TJ, Prentice AM. Human energy expenditure in affluent societies: an analysis of 574 doubly-labelled water measurements. Eur J Clin Nutr 1996; 50: 72.
82. Forbes GB, Reina JC. Adult lean body mass declines with age: some longitudinal observations. Metabolism 1970; 19: 653–663.
83. Guo SS, Chumlea WC, Roche AF, Siervogel RM. Age-and maturity-related changes in body composition during adolescence into adulthood: the Fels Longitudinal Study. Appl Radiat Isot 1998; 49: 581–585.
84. Beckett LA, Rosner B, Roche AF, Guo S. Serial changes in blood pressure from adolescence into adulthood. Am J Epidemiol 1992; 135: 1166–1177.
85. Sutton R. Adult anthropometric measures, overweight and obesity. Health Survey for England–2011. Health, Social Care and Lifestyles 2012; 325–362.
86. Ramaekers JG, van Wel JH, Spronk DB, Toennes SW, Kuypers KPC, Theunissen EL, Verkes RJ. Cannabis and tolerance: acute drug impairment as a function of cannabis use history. Sci Rep 2016; 6: 26843.
87. Schuster RM, Mermelstein RJ, Hedeker D. Ecological momentary assessment of working memory under conditions of simultaneous marijuana and tobacco use. Addiction 2016; 111: 1466–1476.
88. Cooper ZD, Haney M. Investigation of sex-dependent effects of cannabis in daily cannabis smokers. Drug Alcohol Depend 2014; 136: 85–91.
89. Makela P, Wakeley J, Gijsman H, Robson PJ, Bhagwagar Z, Rogers RD. Low doses of Δ-9 tetrahydrocannabinol (THC) have divergent effects on short-term spatial memory in young, healthy adults. Neuropsychopharmacology 2006; 31: 462–470.
90. Anderson BM, Rizzo M, Block RI, Pearlson GD, O'Leary DS. Sex, drugs, and cognition: effects of marijuana. J Psychoactive Drugs 2010; 42: 413–424.
91. Crane NA, Schuster RM, Mermelstein RJ, Gonzalez R. Neuropsychological sex differences associated with age of initiated use among young adult cannabis users. J Clin Exp Neuropsychol 2015; 37: 389–401.